ATE209680T1 - Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen - Google Patents

Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Info

Publication number
ATE209680T1
ATE209680T1 AT96913954T AT96913954T ATE209680T1 AT E209680 T1 ATE209680 T1 AT E209680T1 AT 96913954 T AT96913954 T AT 96913954T AT 96913954 T AT96913954 T AT 96913954T AT E209680 T1 ATE209680 T1 AT E209680T1
Authority
AT
Austria
Prior art keywords
molecules
nucleic acid
acid molecules
hla
mhc
Prior art date
Application number
AT96913954T
Other languages
English (en)
Inventor
Yannick Guilloux
Francine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE209680T1 publication Critical patent/ATE209680T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96913954T 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen ATE209680T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
PCT/US1996/006409 WO1996040039A2 (en) 1995-06-07 1996-05-07 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof

Publications (1)

Publication Number Publication Date
ATE209680T1 true ATE209680T1 (de) 2001-12-15

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913954T ATE209680T1 (de) 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Country Status (12)

Country Link
US (3) US5821122A (de)
EP (1) EP0845032B1 (de)
JP (1) JP3849102B2 (de)
AT (1) ATE209680T1 (de)
AU (1) AU704934B2 (de)
CA (1) CA2223694C (de)
DE (1) DE69617440T2 (de)
DK (1) DK0845032T3 (de)
ES (1) ES2167561T3 (de)
PT (1) PT845032E (de)
WO (1) WO1996040039A2 (de)
ZA (1) ZA963907B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA98656B (en) 1997-01-27 1998-08-17 Ludwig Inst Cancer Res Lage-1 tumer associated nucleic acids
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US20020164654A1 (en) * 2000-01-20 2002-11-07 Rosalie Luiten MAGE antigenic peptides which bind HLA-B35 and HLA-B44
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1268394C (zh) 2001-01-17 2006-08-09 特鲁比昂药品公司 结合域－免疫球蛋白融合蛋白
US6607151B2 (en) 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
EP1684801B1 (de) * 2003-11-21 2009-12-02 Institut Pasteur Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
KR20100092031A (ko) * 2004-06-17 2010-08-19 맨카인드 코포레이션 에피토프 유사체
US8188243B2 (en) * 2004-06-23 2012-05-29 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2011032003A1 (en) 2009-09-10 2011-03-17 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
AU2013273987B2 (en) 2012-06-15 2018-08-09 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
KR20150132479A (ko) 2013-03-15 2015-11-25 어댑티브 바이오테크놀로지스 코포레이션 복합 유전자 세트에서의 독특하게 태그되고 재배열된 적응 면역 수용체 유전자
WO2015058111A1 (en) 2013-10-17 2015-04-23 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and thereapeutic agents
WO2015172153A1 (en) 2014-05-09 2015-11-12 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3512563A1 (de) 2016-09-16 2019-07-24 The Johns Hopkins University Protein-nanocages mit verbesserter schleimpenetration zur gezielten gewebe- und intrazellulären verabreichung
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
EP3615052B1 (de) 2017-04-27 2023-01-25 The University of Hong Kong Verwendung von hcn-inhibitoren zur behandlung von krebs
WO2018237109A1 (en) 2017-06-23 2018-12-27 Yale University NANOMATERIALS HAVING IMPROVED MEDICATION DELIVERY EFFICIENCY
EP4377338A2 (de) 2021-07-27 2024-06-05 Novab, Inc. Manipulierte vlrb-antikörper mit immuneffektorfunktionen
US20230172870A1 (en) 2021-12-08 2023-06-08 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP0687180B1 (de) * 1992-12-22 2000-11-08 Ludwig Institute For Cancer Research Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
ZA963907B (en) 1997-03-11
US5821122A (en) 1998-10-13
EP0845032A2 (de) 1998-06-03
US5958711A (en) 1999-09-28
PT845032E (pt) 2002-05-31
DE69617440D1 (de) 2002-01-10
ES2167561T3 (es) 2002-05-16
DK0845032T3 (da) 2002-05-06
AU5676996A (en) 1996-12-30
WO1996040039A3 (en) 2000-03-23
EP0845032A4 (de) 2000-05-10
JP2001520506A (ja) 2001-10-30
AU704934B2 (en) 1999-05-06
US5886145A (en) 1999-03-23
CA2223694A1 (en) 1996-12-19
JP3849102B2 (ja) 2006-11-22
EP0845032B1 (de) 2001-11-28
WO1996040039A2 (en) 1996-12-19
DE69617440T2 (de) 2002-08-08
CA2223694C (en) 2003-06-24

Similar Documents

Publication Publication Date Title
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69433790T2 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
NO953699D0 (no) Isolerte nukleinsyremolekyler som koder for tumor-rejeksjonsforlöperen MAGE-3, samt anvendelser derav
FI960268A0 (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
DE69511399T2 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA66753C2 (en) Immunostimulator and method for its production
CA2213001A1 (en) Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
CA2165435A1 (en) Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0845032

Country of ref document: EP